My lab is focused on developing potential new anti-cancer agents, with a focus on preventing cancer recurrence. New cancer drugs are first tested in patients with advanced metastatic cancer where they inevitably have limited impact. In recent years this practice has led to the approval of high-cost drugs with only limited medical benefit. Thus the problem faced by oncologists and patients alike is a lack of effective strategies to treat metastatic disease. When used to treat early-stage cancers some drugs have realised far greater value.
Our goal is to develop new treatments for cancer that prevent recurrence. To do this we are developing new therapeutics that specifically target mechanisms that tumours use to escape treatment and recur.